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INTRODUCTION
Apheresis is a Greek word that means to
‘separate’ or ‘remove’. In apheresis, blood is
withdrawn  from a donor or a patient in
anticoagulant solution and separated into
components. One or more components are
retained and the remaining constituents are
returned to the individual.l,2 Plateletpheresis is
a procedure where the whole blood is processed
from a donor and the platelets alone are
separated and the remaining blood components
are returned  back to  the donor. The  cell
separator has been used as a primary tool to
collect  platelet  concentrates.  Technical
advances in automated cell separators have
substantially improved the productivity and
quality of the collection of single donor
platelets.3 Recently the use of single donor
platelet (SDP) concentrates has grown steadily
due  to its  employment in chemotherapy
protocols. This is especially due to lower
alloimmunization and transmission of viruses
to  patients  afforded  by  reduced  donor
exposure.4-8 It is also used in platelet refractory
patients where there is need of human leukocyte
antigen (HLA) matched or human platelet
antigen matched components are warranted.
Wherever platelets transfusions are required,
SDPs can be used as it provides an adequate
therapeutic adult dose.  Increasing demand for
platelet transfusion implies the need to recruit
greater numbers of donors, and ensuring the
safety of the donors is a crucial factor in
recruitment.
As nearly all red blood cells (RBC) and white
blood cells (WBC) can be returned to the donor,
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Background: Recently the use of single donor platelet (SDP) concentrates has grown steadily due to its employment
in chemotherapy protocols. Technical advances in automated cell separators have substantially improved the productivity
and quality of the collection of apheresis platelets.
Methods: We prospectively studied 90 healthy donors who volunteered for plateletpheresis. We compared the pre-
and post-plateletpheresis haematological values, namely, haemoglobin (Hb), haematocrit, platelet count, mean
corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelet distribution
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Results: Following plateletpheresis a significant decrease in pre- and post-donation Hb (g/dL) (14.8 ± 1.097 Vs 14.5
± 1.4; p=0.002); haematocrit (%) (43.29 ± 6.62 Vs 41.64 ± 4.96; p=0.045); platelet count ( 109/L) (280.34 ± 54.55
Vs 175.58 ± 44.56; p< 0.001); WBC count ( 103/μL) (8.28 ± 1.88 Vs 6.95 ± 1.76; p< 0.001); and PDW (fL) (15.96
± 1.38 Vs 4.96 ± 0.67; p=0.053) and a slight rise in MPV (fL) (8.61 ± 0.77 Vs 8.72 ± 0.83; p=0.067) were observed.
However, none of them developed clinical manifestation of anaemia or thrombocytopenia.
Conclusions: Close monitoring and follow-up for these donors is indicated to prevent unfavourable events caused by
these changes.
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it is common practice to repeat apheresis
donations at close intervals. This has raised
concerns that frequent collection of blood cells,
in particular platelets, could result in large cell
losses that could lead to transient clinically
significant problems in donors.9
Now a days, the cell separators can yield high-
dose plateletpheresis, resulting in up to four
units of apheresis platelets for transfusion to
patients.9 However, concerns regarding the
safety of platelet donors run contrary to these
interests and technical possibilities. This can
be easily investigated by measuring the total
platelet counts of normal donors before and
after plateletpheresis. As these hematological
changes may induce clinical implications to the
donor such as thrombocytopenia and anaemia,
the present study was done to investigate the
changes  in  haematological  values  after
plateletpheresis in donors at our blood bank.
MATERIAL  AND  METHODS
This prospective study was conducted in our
department for a period of one year from July
2012 to July 2013. First-time healthy platelet-
pheresis donors were enrolled for SDP during
this period. All the donors were selected
according to the guidelines laid down by Drugs
and Cosmetics Act, 194010 and American
Association of Blood Bank.11 According to our
departmental standard operating procedure,
criteria for eligibility for plateletpheresis were
as  follows: (i) age 18-60 years; (ii) pre-
apheresis platelet count greater than or equal
to 200 × 109/L; (iii) haemoglobin levels greater
than or equal to 12.5 g/dL; (iv) donor body
weight greater than or equal to 65 kg; (v) non-
reactive  test  results  for  human
immunodeficiency virus (HIV) 1, 2 antibodies
and p-24 antigen; hepatitis B surface antigen,
hepatitis C antibody, malaria and syphilis; (vi)
absence of any illness; (vii) time lapse of at
least 3 months since last whole blood donation;
(viii) time lapse of at least 3 days since last
plateletpheresis; and (ix) no consumption of
non-steroidal anti-inflammatory drugs and
acetyl salicylic acid in the last 7 days who were
in good health, were feeling well and had
adequate venous access. Details of platelet-
pheresis procedure were explained to each
donor and the consent was obtained before the
procedure. All donations were performed using
Fresenius Kabi COM.TEC apheresis machine
(Fresenius Kabi AG, Bad Homburg, Germany).
Haematological parameters of the donors were
analysed using calibrated automated analyser
(BC-5300  Auto  Hematology  Analyser,
Shenzhen Mindray; Biomedical Electronics Co.
Ltd, China). Blood flow rate for all collections
was  maintained  at  50-60  mL/min  with
anticoagulant to blood ratio of 1:12. The end-
point was 300 mL of SDP with the target yield
of 3  1011 platelets per unit. Two mL of whole
blood from the donor was collected into
ethylene diamine tetra acetic acid bottles just
before  and  within 30  minutes  after  the
procedures. Pre- and post-plateletpheresis
haematological values, such as, haemoglobin,
haematocrit, platelet count, mean corpuscular
volume (MCV), mean corpuscular haemoglo-
bin (MCH), mean corpuscular haemoglobin
concentration (MCHC), PDW, RBC count and
WBC count were analysed.
Statistical analysis
Data are  presented  as  mean ±  standard
deviation.  The  mean  pre-  and  post-
plateletpheresis values were compared using
paired t-test. Statistical analysis was carried out
using statistical software SPSS version 16. A
p-value  less  than  0.05  was  considered
significant.
RESULTS
During the study period, 90 plateletpheresis
donors were studied. Their mean age was 28 ±
6.61 (range 19-45) years; all were males. Eight
donors (8.9%) were in the age group of 18-20
years; 55 donors (61.1%) were in 21-30 years
age group; 19 donors (21.1%) were in 31-40
years age group; and 8 donors (8.9%) were in
41-50 years age group. Blood group distribution
in them was as followed: O Positive (n=48;
53.3%) B Positive (n=21; 23.3%), A Positive
(n=12; 13.3%), AB Positive (n=5; 5.5%), B
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Negative (n=2; 2.2%) and O Negative (n=2;
2.2%). The mean pre-donation haemoglobin
was 14.8 ± 1.1 g/dL (range 12.6-17.3). The
mean pre-donation platelet count was 280.3 ±
54.6 109/L (range 208-589).  Following
plateletpheresis, the haemoglobin concentration
(p=0.002), haematocrit (p=0.045), and PDW
(p=0.039) significantly decreased in the donors
(Table 1). There was also a significant decrease
in post-donation platelet count (p<0.001) and
WBC count (p<0.001). A decrease in MCV
(p=0.213) and RBC count (p=0.053) was
observed after plateletpheresis but this was not
statistically significant. However, we observed
a slight but statistically insignificant rise in
post-donation MPV in our donors (p=0.067).
Four donors (4.4%) had a post-plateletphersis
haemoglobin level of less than 12 g/dL but no
untoward clinical event occurred either during
or after the procedure. Out of these four donors,
three had a pre-donation haemoglobin levels
greater than 13 g/dL and one had a pre-
plateletpheresis haemoglobin level of 12.7g/dL.
We  observed  two donors (2.2%) to have a
post-procedure platelet count of less than
100109/L; associated clinical manifestations
were not evident.
Two of our donors had donated twice at an
interval  of 5 weeks. But  there were  no
significant  decrease  in  haematological
parameters before or after the second donation.
DISCUSSION
Developments in medical sciences, including
organ  transplantation  programs,  has
significantly  increased  the  demand  for
platelets.12 Collection of platelets by apheresis
has been a major advance in transfusion
medicine and it is advantageous over random
donor platelets. Such SDPs allow supply of a
therapeutically beneficial component ensuring
leucocyte reduction of less than 5  106/unit
thereby decreasing febrile non-haemolytic
transfusion reactions, limited donor exposure
thereby reduced infectious complications and
supply of HLA matched platelet concentrates
in refractory patients.13,14 During the last
decades  there  have  been  significant
improvements in the productivity and quality
of apheresis platelets. Today, more emphasis
is placed on  introducing new  generation
machines that can guarantee consistent product
quality with optimum leukoreduction. Although
such collections from eligible donors have
optimized the availability of platelet and their
transfusions  and, blood  centres are also
emphasizing on donor safety in parallel to
product quality  while performing  these
procedures. However, donor safety issues in
plateletpheresis have, received relatively little
attention. In our present study, donor safety
issues  with  regards  to  reductions  in
haematological values after plateletpheresis
Table 1: Pre-and post-plateletpheresis haematological values
Parameter Pre- donation  Post- donation p-value
Mean±SD Range Mean±SD Range
Hb (g/dl) 14.8±1.097 12.6-17.3 14.5±1.4 10.6-17.3 0.002
Hct (%) 43.29±6.62 36.6-98.3 41.64±4.96 30.1-68.5 0.045
Plt (x109/L) 280.34±54.55 208-589 175.58±44.56 100-295 <0.001
MCV (fL) 84.21±5.16 68-108 83.99±5.12 67.4-106.1 0.213
MPV (fL) 8.61±0.77 6.8-10.9 8.72±0.83 6.8-12.0 0.067
PDW (fL) 15.96±1.38 3.3-16.8 16.27±0.39 15.1-17.8 0.039
RBC (million/µL) 5.08±0.41 4.12-6.03 4.96±0.67 2.28-8.01 0.053
WBC (103/µL) 8.28±1.88 4.6-14 6.95±1.76 2.02-11.13 <0.001
Hb = haemoglobin: Hct = haematocrit; Plt = platelet count; MCV = mean corpuscular volume;
MPV = mean platelet volume; PDW = platelet distribution width
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were addressed. In our study, a significant
reduction in platelet and WBC count was
observed post-plateletpheresis. In another
study15 evaluating the effect of various cell
separators on donor haematological parameters
reported that platelet count and WBC count
decreased  significantly  when  Fresenius
COM.TEC cell separator was used. So the
highly significant decrease platelet count and
WBC count reported in our study could be
because of the use of the Fresenius COM.TEC
cell separator. Our data showed that after the
procedure, values for haemoglobin (p=0.002),
haematocrit (p=0.045), and PDW (p=0.039)
decreased significantly in the donors. Similar
results were reported in other studies.16,17
However, in another study,18 a decrease in Hb,
Hct and WBC count and an increase in platelet
count were observed post-plateletpheresis. The
decrease in values in our study could be as a
result of infusions of anticoagulant solutions
and 0.9% normal saline during the procedure19
or it could be due to blood loss in the residual
volume of  apheresis kit. We observed  a
decrease in MCV and RBC, but these changes
were not clinically significant. We observed a
slight increase in MPV which has also been
reported in another study.15 In our study 2.2%
of donors had a decrease in platelet count less
than 100x109/L post-procedure without any
associated clinical manifestations. In another
study20 also a similar post-procedure decline in
platelet count to less than 100  109/L had been
reported in 2.1% of donors. Some workers15
have reported that decrease in platelet count
could  be  a  concern  for  clinical
thrombocytopenia  in donors who have a
predonation platelet count of  less than 200 
109/L. But in our study, none of the donors had
a pre-donation platelet count of  less than 200
 109/L. This is because, according to our
departmental standard operating procedure,
only those donors who have a platelet count of
200  109/L or above were taken up for
donation. It has been recommended that donors
who have a low or borderline pre-donation
platelet count and haemoglobin levels should
be assessed and monitored post-donation for
decrements in haematological parameters.21 A
significant and sustained decrease in platelet
count for all donation frequency categories has
been documented in an earlier report but none
of the donors had clinical thrombocytopenia.22
Moreover, the relative safety and efficacy of
repeat plateletpheresis procedures when a
single donor was committed to a maintenance
regime for a designated patient has been
reported.23 It has also been observed that even
triple plateletpheresis procedure does not result
in either short-term post-apheresis thrombo-
cytopenia or long-term donor platelet depletion
also and it was independent of the type of
apheresis machine used.9 Though the mean
platelet count decreased significantly post-
plateletpheresis in our study, there were no
clinical symptoms like prolonged bleeding from
the phlebotomy site, petechiae or purpura.
Further, the post-donation platelet count did not
decrease below 100   109/L. It has been
reported that plateletpheresis was associated
with statistically but not clinically important
decrease in platelet count in another study.24
Under a situation of limited human resources
and shrinking donor population, both platelet
availability and donor safety should go hand in
hand. In our study, donor safety was ensured
throughout the procedure. Though a significant
decrease in the post-procedure haematological
values were evident the donors, no significant
clinical manifestations were evident. We
recommend that haematological parameters
have to be tested following the procedure in
plateletpheresis donors. This will be of value
in establishing post-donation reference ranges
which could be utilized when reviewing the
suitability of donors for subsequent donations
thereby ensuring both donor safety and product
quality. Further studies on close monitoring and
follow-up of these donors are needed in order
to look for any long-term consequences.
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